Costimulation blockade: Current perspectives and implications for therapy

Transplantation

Volumn 95, Issue 4, 2013, Pages 527-535

  Kinnear, Gillian ^a   Jones, Nick D ^b   Wood, Kathryn J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Biologic therapeutics; CTLA 4; Immunoregulation; Immunosuppression; Rejection; T cell activation; Transplantation

Indexed keywords

BELATACEPT; CD134 ANTIGEN; CD137 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD70 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EFALIZUMAB; INDUCIBLE T CELL COSTIMULATOR; INTERLEUKIN 2; OX40 LIGAND; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL 2; RAPAMYCIN; STEROID; T LYMPHOCYTE RECEPTOR; TGN 1412;

ACUTE GRAFT REJECTION; ANTIBODY RESPONSE; AUTOIMMUNITY; CARDIAC ALLOGRAFT VASCULOPATHY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOKINE STORM; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; EFFECTOR CELL; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; KIDNEY TRANSPLANTATION; LONG TERM SURVIVAL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MEMORY CELL; NONHUMAN; PHARMACOLOGICAL BLOCKING; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN PROTEIN INTERACTION; PSORIASIS; REVIEW; T LYMPHOCYTE ACTIVATION; TH17 CELL; THROMBOEMBOLISM; TRANSPLANTATION TOLERANCE;

ANIMALS; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; DRUG DESIGN; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIGANDS; LYMPHOCYTE ACTIVATION; ORGAN TRANSPLANTATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 84874644839     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31826d4672     Document Type: Review

References (112)

1. Shelton MW, Walp LA, Basler JT, et al. Mediation of skin allograft rejection in scid mice by CD4+ and CD8+ T cells. Transplantation 1992; 54: 278.
2. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation 2012; 93: 1.
3. Zinkernagel RM, Doherty PC. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature 1974; 251: 547.
4. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248: 701.
5. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989; 7: 445.
6. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature reviews. Immunology 2003; 3: 133.
7. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970; 169: 1042.
8. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev 2009; 229: 271.
9. Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: issues in perspective. Transplantation 2011; 91: 1057.
10. June CH, Bluestone JA, Nadler LM, et al. The B7 and CD28 receptor families. Immunol Today 1994; 15: 321.
11. Jenkins MK. The ups and downs of T cell costimulation. Immunity 1994; 1: 443.
12. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11: 191.
13. Fraser JD, Irving BA, Crabtree GR, et al. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991; 251: 313.
14. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995; 3: 87.
15. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561.
16. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405.
17. Finger EB, Bluestone JA. When ligand becomes receptorYtolerance via B7 signaling on DCs. Nat Immunol 2002; 3: 1056.
18. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097.
19. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165.
20. Damle NK, Doyle LV, Grosmaire LS, et al. Differential regulatory signals delivered by antibody binding to the CD28 (Tp44) molecule during the activation of human T lymphocytes. J Immunol 1988; 140: 1753.
21. Baliga P, Chavin KD, Qin L, et al. CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity. Transplantation 1994; 58: 1082.
22. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 11102.
23. Kawai K, Shahinian A, Mak TW, et al. Skin allograft rejection in CD28-deficient mice. Transplantation 1996; 61: 352.
24. Pearson TC, Alexander DZ, Corbascio M, et al. Analysis of the B7 costimulatory pathway in allograft rejection. Transplantation 1997; 63: 1463.
25. Reddy B, Gupta S, Chuzhin Y, et al. The effect of CD28/B7 blockade on alloreactive T and B cells after liver cell transplantation. Transplantation 2001; 71: 801.
26. Glysing-Jensen T, Raisanen-Sokolowski A, Sayegh MH, et al. Chronic blockade of CD28-B7-mediated T-cell costimulation by CTLA4Ig reduces intimal thickening in MHC class I and II incompatible mouse heart allografts. Transplantation 1997; 64: 1641.
27. Judge TA, Tang A, Turka LA. Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Immunol Res 1996; 15: 38.
28. Azuma H, Chandraker A, Nadeau K, et al. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci USA 1996; 93: 12439.
29. Chandraker A, Azuma H, Nadeau K, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998; 101: 2309.
30. Hayward AR, Levy J, Facchetti F, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 1997; 158: 977.
31. Blotta MH, Marshall JD, DeKruyff RH, et al. Cross-linking of the CD40 ligand on human CD4+ T lymphocytes generates a costimulatory signal that up-regulates IL-4 synthesis. J Immunol 1996; 156: 3133.
32. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr Opin Immunol 1997; 9: 641.
33. Blair PJ, Riley JL, Harlan DM, et al. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 2000; 191: 651.
34. Hancock WW, Sayegh MH, Zheng XG, et al. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci USA 1996; 93: 13967.
35. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
36. Parker DC, Greiner DL, Phillips NE, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995; 92: 9560.
37. Kenyon NS, Chatzipetrou M, Masetti M, et al. Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci USA 1999; 96: 8132.
38. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5: 686.
39. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789.
40. Meng L, Wu Z, Wang Y, et al. Differential impact of CD154 costimulation blockade on alloreactive effector and regulatory T cells in murine renal transplant recipients. Transplantation 2008; 85: 1332.
41. Azimzadeh AM, Pfeiffer S, Wu G, et al. Alloimmunity in primate heart recipients with CD154 blockade: evidence for alternative costimulation mechanisms. Transplantation 2006; 81: 255.
42. Gilson CR, Milas Z, Gangappa S, et al. Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation. J Immunol 2009; 183: 1625.
43. Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007; 84: 1020.
44. Li XL, Menoret S, Le Mauff B, et al. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation. Transplantation 2008; 86: 10.
45. Dong C, Juedes AE, Temann UA, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001; 409: 97.
46. Tafuri A, Shahinian A, Bladt F, et al. ICOS is essential for effective Thelper-cell responses. Nature 2001; 409: 105.
47. Dong C, Temann UA, Flavell RA. Cutting edge: critical role of inducible costimulator in germinal center reactions. J Immunol 2001; 166: 3659.
48. Ozkaynak E, Gao W, Shemmeri N, et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001; 2: 591.
49. Harada H, Salama AD, Sho M, et al. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest 2003; 112: 234.
50. Burmeister Y, Lischke T, Dahler AC, et al. ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol 2008; 180: 774.
51. Guillonneau C, Aubry V, Renaudin K, et al. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade. Transplantation 2005; 80: 255.
52. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111.
53. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319.
54. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141.
55. Sandner SE, Clarkson MR, Salama AD, et al. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol 2005; 174: 3408.
56. Gao W, Demirci G, Strom TB, et al. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation 2003; 76: 994.
57. Calderhead DM, Buhlmann JE, van den Eertwegh AJ, et al. Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J Immunol 1993; 151: 5261.
58. al-Shamkhani A, Birkeland ML, Puklavec M, et al. OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur J Immunol 1996; 26: 1695.
59. Gramaglia I, Weinberg AD, Lemon M, et al. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998; 161: 6510.
60. Rogers PR, Song J, Gramaglia I, et al. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001; 15: 445.
61. Curry AJ, Chikwe J, Smith XG, et al. OX40 (CD134) blockade inhibits the co-stimulatory cascade and promotes heart allograft survival. Transplantation 2004; 78: 807.
62. Kinnear G, Wood KJ, Marshall D, et al. Anti-OX40 prevents effector T-cell accumulation and CD8+ T-cell mediated skin allograft rejection. Transplantation 2010; 90: 1265.
63. Chen M, Xiao X, Demirci G, et al. OX40 controls islet allograft tolerance in CD154 deficient mice by regulating FOXP3+ Tregs. Transplantation 2008; 85: 1659.
64. Valzasina B, Guiducci C, Dislich H, et al. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005; 105: 2845.
65. Pollok KE, Kim YJ, Zhou Z, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993; 150: 771.
66. Langstein J, Michel J, Fritsche J, et al. CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J Immunol 1998; 160: 2488.
67. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186: 47.
68. Wang J, Guo Z, Dong Y, et al. Role of 4-1BB in allograft rejection mediated by CD8+ T cells. Am J Transplant 2003; 3: 543.
69. Cho HR, Kwon B, Yagita H, et al. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival. Transpl Int 2004; 17: 351.
70. Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med 2003; 198: 1369.
71. Tesselaar K, Xiao Y, Arens R, et al. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol 2003; 170: 33.
72. Gravestein LA, Borst J. Tumor necrosis factor receptor family members in the immune system. Semin Immunol 1998; 10: 423.
73. Shariff H, Greenlaw RE, Meader L, et al. Role of the Fc region in CD70-specific antibody effects on cardiac transplant survival. Transplantation 2011; 92: 1194.
74. Yamada A, Salama AD, Sho M, et al. CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo. J Immunol 2005; 174: 1357.
75. Nicolls MR, Coulombe M, Yang H, et al. Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4. J Immunol 2000; 164: 3627.
76. Paul LC, Davidoff A, Benediktsson H, et al. The efficacy of LFA-1 and VLA-4 antibody treatment in rat vascularized cardiac allograft rejection. Transplantation 1993; 55: 1196.
77. Molossi S, Elices M, Arrhenius T, et al. Blockade of very late antigen-4 integrin binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts. J Clin Invest 1995; 95: 2601.
78. Yang H, Issekutz TB, Wright JR Jr. Prolongation of rat islet allograft survival by treatment with monoclonal antibodies against VLA-4 and LFA-1. Transplantation 1995; 60: 71.
79. Kitchens WH, Haridas D, Wagener ME, et al. Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cells. Am J Transplant 2012; 12: 69.
80. Freeman GJ, Casasnovas JM, Umetsu DT, et al. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev 2010; 235: 172.
81. Umetsu SE, Lee WL, McIntire JJ, et al. TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol 2005; 6: 447.
82. Meyers JH, Chakravarti S, Schlesinger D, et al. TIM-4 is the ligand for TIM-1, and the TIM-1-TIM-4 interaction regulates T cell proliferation. Nat Immunol 2005; 6: 455.
83. Degauque N, Mariat C, Kenny J, et al. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest 2008; 118: 735.
84. Ueno T, Habicht A, Clarkson MR, et al. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest 2008; 118: 742.
85. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992; 257: 789.
86. Xu H, Tadaki DK, Elster EA, et al. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation 2002; 74: 940.
87. Kirk AD. Crossing the bridge: large animal models in translational transplantation research. Immunol Rev 2003; 196: 176.
88. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
89. www.accessdata.fdagov/drugsatfda-docs/label/2011/125288s00001b1.pdf. Accessed October 17, 2012.
90. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
91. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011; 91: 976.
92. Krummey SM, Ford ML. Heterogeneity within T cell memory: implications for transplant tolerance. Front Immunol 2012; 3: 36.
93. Brook MO, Wood KJ, Jones ND. The impact of memory T cells on rejection and the induction of tolerance. Transplantation 2006; 82: 1.
94. Valujskikh A, Pantenburg B, Heeger PS. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002; 2: 501.
95. Zhai Y, Meng L, Gao F, et al. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol 2002; 169: 4667.
96. Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 1994; 152: 2675.
97. Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587.
98. Larsen CP, Grinyo J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFITEXT studies. Transplantation 2010; 90: 1528.
99. Grinyo J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010; 90: 1521.
100. Klintmalm GB FS, Lake JR, Vargas HE, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II study [oral abstract #355]. Am J Transplant 2011; 11: 137.
101. Shiao SL, McNiff JM, Masunaga T, et al. Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities. Transplantation 2007; 83: 304.
102. Graves SS, Stone DM, Loretz C, et al. Antagonistic and agonistic anticanine CD28 monoclonal antibodies: tools for allogeneic transplantation. Transplantation 2011; 91: 833.
103. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018.
104. Zhang T, Zhou H, Wu G, et al. Selective Ligation of Cd28 By A Single-Chain Fv Inhibits T Cell Proliferation and Promotes Allograft Survival. Transplantation 2004; 78: 569.
105. Poirier N, Blancho G, Vanhove B. CD28-Specific immunomodulating antibodies: what can be learned from experimental models? Am J Transplant 2012; 12: 1682.
106. Couzin J. Drug discovery. Magnificent obsession. Science 2005; 307: 1712.
107. Badell IR, Thompson PW, Turner AP, et al. Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates. Am J Transplant 2012; 12: 126.
108. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007; 7: 1770.
109. Kitchens WH, Larsen CP, Ford ML. Integrin antagonists for transplant immunosuppression: panacea or peril? Immunotherapy 2011; 3: 305.
110. Carson KR, Focosi D, Major EO, et al. Monoclonal antibodyassociated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816.
111. Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008; 86: 1474.
112. Vincenti F, Larsen CP, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. NEJM 2005; 353: 770.